STATCenter·
STAT+: FDA discloses reasons for rejecting Summit drug
The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
Read at STAT →
The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:

<iframe src="https://statesidedaily.com/embed/cluster/8e9ff695d190c494bb0a9f06c0734e422952e77c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: FDA discloses reasons for rejecting Summit drug"></iframe>